Urate levels in LRRK2 mutation carriers may determine susceptibility for Parkinson’s disease

Takeaway

  • In carriers of leucine-rich repeat kinase 2 (LRRK2) mutations, higher level of the antioxidant urate is associated with a reduced odds of Parkinson’s disease (PD).

Why this matters ?

  • Measuring urate levels in LRRK2 mutation carriers may be an effective method of assessing the risk of developing PD.